Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is -54.95% lower on its value in year-to-date trading and has touched a low of $1.19 and a high of $3.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The XERS stock was last observed hovering at around $1.27 in the last trading session, with the day’s gains setting it 0.05% off its average median price target of $5.50 for the next 12 months. It is also 78.0% off the consensus price target high of $6.00 offered by 4 analysts, but current levels are 67.0% higher than the price target low of $4.00 for the same period.
Currently trading at $1.32, the stock is -10.39% and -11.60% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.9 million and changing 3.94% at the moment leaves the stock -31.35% off its SMA200. XERS registered -36.54% loss for a year compared to 6-month loss of -32.99%.
The stock witnessed a -15.38% gain in the last 1 month and extending the period to 3 months gives it a -23.26%, and is -1.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.79% over the week and 5.71% over the month.
Xeris Biopharma Holdings Inc. (XERS) has around 294 employees, a market worth around $172.70M and $98.50M in sales. Distance from 52-week low is 10.92% and -58.34% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.80%).
Xeris Biopharma Holdings Inc. (XERS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Xeris Biopharma Holdings Inc. (XERS) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Xeris Biopharma Holdings Inc. is expected to release its quarterly report on 03/09/2023.The EPS is expected to grow by 27.30% this year
Xeris Biopharma Holdings Inc. (XERS) Top Institutional Holders
The shares outstanding are 135.95M, and float is at 132.35M with Short Float at 4.75%.
Xeris Biopharma Holdings Inc. (XERS) Insider Activity
A total of 7 insider transactions have happened at Xeris Biopharma Holdings Inc. (XERS) in the last six months, with sales accounting for 0 and purchases happening 7 times. The most recent transaction is an insider purchase by Edick Paul R, the company’s. SEC filings show that Edick Paul R bought 100,000 shares of the company’s common stock on May 12 at a price of $1.40 per share for a total of $0.14 million. Following the purchase, the insider now owns 1.51 million shares.
Xeris Biopharma Holdings Inc. disclosed in a document filed with the SEC on Feb 22 that PRESTRELSKI STEVEN (Chief Scientific Officer) sold a total of 11,228 shares of the company’s common stock. The trade occurred on Feb 22 and was made at $2.42 per share for $27158.0. Following the transaction, the insider now directly holds 0.57 million shares of the XERS stock.